Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (note: metadata lists "Scinai Immunotherapeutics Ltd." but the filing text identifies "BiondVax Pharmaceuticals Ltd.") covers the month of December 2021. The report was filed on December 27, 2021, to disclose a corporate financing event.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the pricing of a follow-on underwritten offering of American Depositary Shares totaling $9.0 million.
Material Changes
The material change reported is the completion of a capital raise. On December 27, 2021, the company announced the pricing of the $9.0 million offering. No comparative financial data or changes in operational metrics versus prior periods are included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, risk factors, or contingencies beyond the announcement of the share offering. The document serves primarily as a notification of the press release filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the final closing date and net proceeds of the $9.0 million follow-on offering.
- Confirm the number of American Depositary Shares issued and the offering price per share.
- Review the full text of the press release (Exhibit 99.1) for details on the use of proceeds.
- Check subsequent filings for updated cash position and dilution impact on existing shareholders.